| abstract |
The present invention relates to the (S) -enantiomer of an aminoheteroaryl compound used for the treatment and / or prevention of cancer in a subject. The invention further relates to pharmaceutical compositions comprising said compounds. Another aspect of the present invention is an in vitro method for determining the efficacy of the (S) -enantiomer of the aminoheteroaryl compound or the pharmaceutical composition, wherein (a) obtaining a cell or tissue sample from a subject And (b) determining the NUDT1 / MTH1 status of the subject, wherein the NUDT1 / MTH1-positive cell or tissue sample is an indicator of effective cancer treatment and / or prevention. In addition, screening methods for identifying the target of the (S) -enantiomer of an aminoheteroaryl compound are presented herein. Furthermore, in the present invention, the compounds described herein inhibit the biological activity of MTH1. [Selection figure] None |